Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Diabetes

Diabetes

Recruiting

Investigating islet cell infusion in people with type 1 diabetes and kidney transplant

The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for patients with type 1 diabetes who have a kidney transplant.

Status
Recruiting
Principal Investigator
Breay Paty
Body Locations and Systems
Endocrine System
Age
18-65

Studying the safety of Montbretin A for diabetes

The purpose of this study is to investigate the safety and tolerability of Montbretin A, a new natural health product made from garden flower, in treating healthy individuals or individuals with type 2 diabetes by reducing hyperglycemia episodes.

Status
Recruiting
Principal Investigator
Robert Petrella
Age
19-65

Evaluating the efficacy of islet cell therapy for type 1 diabetes

The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for type 1 diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar. 

Status
Recruiting
Principal Investigator
Breay Paty
Body Locations and Systems
Endocrine System
Age
18-65

Evaluating a virtual program for peer-led mental health support

The purpose of this study is to evaluate a peer-led mental health support program, REACHOUT, for rural and remote communities in British Columbia. REACHOUT is a mobile app that provides free peer-led mental health support to adults with type 1 diabetes (T1D). The REACHOUT intervention spans over six months and empowers adults with T1D to join as either a peer supporter, who will be trained to provide social and emotional assistance, or as a participant, who will receive invaluable support from empathetic peer supporters.

Status
Recruiting
Principal Investigator
Tricia Tang
Body Locations and Systems
Endocrine System
Age
19 and above

Glucose Variability in Subclinical Hypertrophy

Evaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption. In this study investigators propose to enroll at least 20 people who participated in phase 1 and who were determined to have subclinical lipohypertrophy to examine the correlation between glycemic control and amount of insulin injected in subclinical hypertrophic areas using capillary blood glucose and continuous glucose monitoring.

Status
Recruiting
Principal Investigator
Graydon Meneilly
Body Locations and Systems
Diabetes - Type 1
Diabetes - Type 2
Area
Vancouver
Age
19 and above

From Clinic to Community Study (C2C)

This study is a 12-month study. There are two different groups in the study. Both groups will enter the study after the graduation from 8-hour diabetes education course taught at VGH, St. Paul's, or Richmond Hospital. The first group will receive on-going support from their peers who have diabetes and are trained specifically to help other patients with diabetes. The second group will receive the usual care.

Status
Recruiting
Principal Investigator
Tricia Tang
Body Locations and Systems
Diabetes - Type 2
Area
Vancouver
Age
21 and above

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)

In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections. Even with insulin injections, blood glucose (sugar) control is imperfect and leads to many health complications and a shortened life span. This is a pilot clinical trial to test the safety of a drug, ustekinumab, in 20 adult subjects with recent-onset T1D.

Status
Recruiting
Principal Investigator
Thomas Elliott
Body Locations and Systems
Diabetes - Type 1
Area
Vancouver
Age
18-35

A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf (Astellas)

While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation have not been achieved. The specific drug combination that provides the best outcomes with the least amount of side effects is not known. Each kidney transplant center uses the combination of drugs that they believe is optimal.

Status
Recruiting
Principal Investigator
Jagbir Gill
Body Locations and Systems
Kidney Transplantation
Area
Vancouver
Age
19 and above

Closed for Recruitment

BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY (BLADE)

The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post procedure in patients with diabetes mellitus (DM).

Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in patients with DM.

Status
Closed for Recruitment
Principal Investigator
David Wood
Body Locations and Systems
Diabetic Heart Disease
Area
Vancouver
Age
18 and above

Bexagliflozin Efficacy and Safety Trial (BEST)

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.

The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.

Status
Closed for Recruitment
Principal Investigator
G.B. John Mancini
Body Locations and Systems
Diabetes - Type 2
Area
Vancouver
Age
40 and above

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

Status
Closed for Recruitment
Principal Investigator
Nadia Zalunardo
Body Locations and Systems
Diabetic Kidney Problems
Diabetes - Type 2
Area
Vancouver
Age
30 and above

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

Status
Closed for Recruitment
Principal Investigator
Graham Wong
Body Locations and Systems
Diabetes - Type 2
Coronary Artery Disease
Area
Vancouver
Age
40 and above

Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V)

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent of 20/32 or worse) were eligible. Eyes that have central-involved DME with "good" visual acuity (20/25 or better) have not been addressed systematically by recent studies for treatment of DME.

Status
Closed for Recruitment
Principal Investigator
David Maberley
Body Locations and Systems
Macular Edema
Area
Vancouver
Age
18 and above

Effects of Sedentary Behaviour on Metabolic Parameters

The rates of sedentary activity are increasing. Studies have shown that time spent on doing sedentary activities is an independent risk factor for cardiovascular disease. Prior studies have shown that interrupting inactivity improved the body's handling of blood glucose and gene expression. The investigators plan to explore this further by examining the effects of interrupting 4 hours of inactivity with 2 minutes of moderate intensity exercise every 20 minutes on the following metabolic parameters: blood pressure, cortisol, C-Reactive Protein, glucose and insulin levels.

Status
Closed for Recruitment
Principal Investigator
Kenneth Madden
Body Locations and Systems
Diabetes - Type 2
Area
Vancouver
Age
65 and above
Subscribe to Diabetes

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy